Who Paid My Doc
Nulibry
Drug Metal Metabolism/Inborn Errors
NDC 73129-001-01
General payments
$715,186
Research payments
$0
Through program year 2025, $715,186 in general payments and $0 in research payments were reported against Nulibry (Metal Metabolism/Inborn Errors).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $137,899 | 21 |
| 2024 | General | $234,759 | 21 |
| 2023 | General | $237,678 | 17 |
| 2022 | General | $104,850 | 7 |
Breakdown
The top 5 of 10 recipients; each share is of general payments naming this product in 2025.
Each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
Each share is of general payments naming this product in 2025 where a state was reported.
Records
66 generalEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.